Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer

Takahiko Murayama(Fox Chase Cancer Center), Jun Nakayama(Osaka International Cancer Institute), Xinpei Jiang(Fox Chase Cancer Center), Kenichi Miyata(Japanese Foundation For Cancer Research), Alexander D. Morris(Fox Chase Cancer Center), Kathy Q. Cai(Fox Chase Cancer Center), Rahul M. Prasad(Fox Chase Cancer Center), Xueying Ma(Fox Chase Cancer Center), Andrey Efimov(Fox Chase Cancer Center), Neel Belani(Fox Chase Cancer Center), Emily R. Gerstein(Fox Chase Cancer Center), Yinfei Tan(Fox Chase Cancer Center), Yan Zhou(Fox Chase Cancer Center), William Kim(UC San Diego Health System), Reo Maruyama(Japanese Foundation For Cancer Research), Kerry S. Campbell(Fox Chase Cancer Center), Lü Chen(Fox Chase Cancer Center), Yibin Yang(Fox Chase Cancer Center), Siddharth Balachandran(Fox Chase Cancer Center), Israel Cañadas(Fox Chase Cancer Center)
Cancer Discovery
January 4, 2024
Cited by 98Open Access
Full Text

Abstract

Activating innate immunity in cancer cells through cytoplasmic nucleic acid sensing pathways, a phenomenon known as "viral mimicry," has emerged as an effective strategy to convert immunologically "cold" tumors into "hot." Through a curated CRISPR-based screen of RNA helicases, we identified DExD/H-box helicase 9 (DHX9) as a potent repressor of double-stranded RNA (dsRNA) in small cell lung cancers (SCLC). Depletion of DHX9 induced accumulation of cytoplasmic dsRNA and triggered tumor-intrinsic innate immunity. Intriguingly, ablating DHX9 also induced aberrant accumulation of R-loops, which resulted in an increase of DNA damage-derived cytoplasmic DNA and replication stress in SCLCs. In vivo, DHX9 deletion promoted a decrease in tumor growth while inducing a more immunogenic tumor microenvironment, invigorating responsiveness to immune-checkpoint blockade. These findings suggest that DHX9 is a crucial repressor of tumor-intrinsic innate immunity and replication stress, representing a promising target for SCLC and other "cold" tumors in which genomic instability contributes to pathology. SIGNIFICANCE: One promising strategy to trigger an immune response within tumors and enhance immunotherapy efficacy is by inducing endogenous "virus-mimetic" nucleic acid accumulation. Here, we identify DHX9 as a viral-mimicry-inducing factor involved in the suppression of double-stranded RNAs and R-loops and propose DHX9 as a novel target to enhance antitumor immunity. See related commentary by Chiappinelli, p. 389. This article is featured in Selected Articles from This Issue, p. 384.


Related Papers

No related papers found

Powered by citation graph analysis